SK Biopharm signs XCOPRI supply contract
에스케이바이오팜
326030
Signal Score
Historical Avg Return (5d)
+1.14%
Data Coverage
100%n=626
Risk-adjusted indicator based on 626 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Contract Amount: 41.61 Billion KRW (USD 27.60 Million)
- • Percentage of Recent Revenue: 5.9%
2 more figures — Starter & Pro plans
AI Analysis Summary
SK Biopharmaceuticals Co., Ltd. signed a supply contract for its epilepsy drug, cenobamate (XCOPRI®), with its US subsidiary, SK Life Science, Inc. The contract is valued at 41.61 billion KRW (USD 27.60 million), representing 5.9% of the company's 2025 consolidated revenue of 706.74 billion KRW. This is an internal transaction for US market sales and will not be recognized as revenue on the consolidated financial statements. The contract period is from May 27, 2026, to May 28, 2026.
Risk Factors
Pro plan
Access Full Korean Market Signal Analytics
✔ AI-parsed DART filing classification & scoring
✔ Real-time event impact indicators
✔ Price reaction & historical pattern data
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.